Expression of concern for

• Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence.

  Fiorucci S, Distrutti E, Mencarelli A, Rizzo G, Lorenzo AR, Baldoni M, Del Soldato P, Morelli A, Wallace JL. Fiorucci S, et al. J Pharmacol Exp Ther. 2004 Jun;309(3):1174-82. doi: 10.1124/jpet.103.063651. Epub 2004 Feb 4. J Pharmacol Exp Ther. 2004. PMID: 14762100
• Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection.

  Fiorucci S, Di Lorenzo A, Renga B, Farneti S, Morelli A, Cirino G. Fiorucci S, et al. J Pharmacol Exp Ther. 2004 Dec;311(3):1264-71. doi: 10.1124/jpet.104.072843. Epub 2004 Aug 5. J Pharmacol Exp Ther. 2004. PMID: 15297470
• A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.

  Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pruzanski M, Morelli A, Pellicciari R. Fiorucci S, et al. J Pharmacol Exp Ther. 2005 Aug;314(2):584-95. doi: 10.1124/jpet.105.084905. Epub 2005 Apr 28. J Pharmacol Exp Ther. 2005. PMID: 15860571
• Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.

  Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R. Fiorucci S, et al. J Pharmacol Exp Ther. 2005 Oct;315(1):58-68. doi: 10.1124/jpet.105.085597. Epub 2005 Jun 24. J Pharmacol Exp Ther. 2005. PMID: 15980055
• Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels.

  Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Antonelli E, Roviezzo F, Morelli A, Cirino G, Wallace JL, Fiorucci S. Distrutti E, et al. J Pharmacol Exp Ther. 2006 Jan;316(1):325-35. doi: 10.1124/jpet.105.091595. Epub 2005 Sep 28. J Pharmacol Exp Ther. 2006. PMID: 16192316